Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Bella Mehta bella_mehta
3 months 2 weeks ago
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
Janet Pope Janetbirdope
3 months 2 weeks ago
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
PA Juge Juge_P_A
3 months 2 weeks ago
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Do the clinical features of axSpA patients with and without IBD differ?
In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.
Dr. John Cush RheumNow
3 months 2 weeks ago
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Annals of the Rheumatic Diseases ARD_BMJ
3 months 2 weeks ago
New hypothesis are explored in #Sjogren
#EULAR2024
CB https://t.co/0glF5BGVO5
Annals of the Rheumatic Diseases ARD_BMJ
3 months 2 weeks ago
Major pathogenic characteristics of #Sjogren disease
#EULAR2024
CB https://t.co/3NeBBKIVT4
Annals of the Rheumatic Diseases ARD_BMJ
3 months 2 weeks ago
Did the patient fail on therapy or are the therapies failing the patient? 🤔
Difficult to to manage psoriatic arthritis: A suggested approach
#EULAR2024
NZ https://t.co/lYvXEX7dp3
Peter Nash drpnash
3 months 2 weeks ago
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Janet Pope Janetbirdope
3 months 2 weeks ago
#Editor’s #Choice
@MatsJunek
Who #relapses in
#ANCA #vasculitis
In #Pexivas trial
#Renal #failure may be protective from relapses.
Seems to be the case in renal #lupus #GN too~my opinion
?Why 🤷
#EULAR2024 #EULARBEST @ARD_BMJ
@RheumNow @eular_org @ACR_Journals https://t.co/kUD1qjnwqE
